Study of BHV-1400 in IgA Nephropathy
Recruiting · NCT07054684 · Interventional (participants receive a specific treatment) · Lead sponsor: Biohaven Therapeutics Ltd.
View the official record on ClinicalTrials.gov →Interventions studied
BHV-1400
What this trial is about
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- \. Participants must have biopsy-confirmed IgA Nephropathy
- Key
Exclusion criteria
- Any secondary IgAN
- Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause
Where it is running
15 locations listed across 10 US states.
- Site-001 - Farmington, Connecticut, United States
- Site-003 - Miami Lakes, Florida, United States
- Site-011 - Miami Lakes, Florida, United States
- Site-013 - Orlando, Florida, United States
- Site-005 - Pembroke Pines, Florida, United States
- Site-008 - Lawrenceville, Georgia, United States
- Site-009 - Hinsdale, Illinois, United States
- Site-012 - Indianapolis, Indiana, United States
- Site-015 - Shelby, Michigan, United States
- Site-006 - Chesterfield, Missouri, United States
- Site-002 - Dakota Dunes, South Dakota, United States
- Site-014 - Houston, Texas, United States
- Site-004 - Houston, Texas, United States
- Site-016 - Salt Lake City, Utah, United States
- Site-007 - Leicester, United Kingdom